A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 287 participants.

Also called NCT01218204

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 287 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01218204
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01218204. Randomized; triple masking; primary purpose treatment. Start 2010-09-14 (actual); primary completion 2011-06-29 (actual). Results posted on 2017-11-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
Condition
Dyslipidaemias
Condition
Dyslipidemias
Intervention (Drug)
10mg atorvastatin
Intervention (Drug)
80mg atorvastatin
Intervention (Drug)
GSK1292263 Placebo
Intervention (Drug)
100mg GSK1292263
Intervention (Drug)
300mg GSK1292263
Intervention (Drug)
800mg GSK1292263
Intervention (Drug)
10mg ezetimibe
Intervention (Other)
Washout
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01218204
Content hash
f12ff4df593fdde97dad8dfe8b0f86f6e21da2b804287cf47100fc908d993158